Investigation Relevant to the Conformation of the 17-Membered Pt(d(GpG)) Macrocyclic Ring Formed by Pt Anticancer Drugs with DNA: Pt Complexes with a Goldilocks Carrier Ligand
- 13 June 2011
- journal article
- Published by American Chemical Society (ACS) in Inorganic Chemistry
- Vol. 50 (14), 6626-6636
- https://doi.org/10.1021/ic200512m
Abstract
Platinum anticancer drug DNA intrastrand cross-link models, LPt(d(G*pG*)) (G* = N7-platinated G residue, L = R4dt = bis-3,3′-(5,6-dialkyl)-1,2,4-triazine), and R = Me or Et), undergo slow Pt–N7 bond rotation. NMR evidence indicated four conformers (HH1, HH2, ΔHT1, and ΛHT2); these have different combinations of guanine base orientation (head-to-head, HH, or head-to-tail, HT) and sugar–phosphodiester backbone propagation relative to the 5′-G* (the same, 1, or opposite, 2, to the direction in B DNA). In previous work on LPt(d(G*pG*)) adducts, Pt–N7 rotation was too rapid to resolve conformers (small L with bulk similar to that in active drugs) or L was too bulky, allowing formation of only two or three conformers; ΛHT2 was not observed under normal conditions. The (R4dt)Pt(d(G*pG*)) results support our initial hypothesis that R4dt ligands have Goldilocks bulk, sufficient to slow G* rotation but insufficient to prevent formation of the ΛHT2 conformer. Unlike the (R4dt)Pt(5′-GMP)2 adducts, ROESY spectra of (R4dt)Pt(d(G*pG*)) adducts showed no EXSY peaks, a result providing clear evidence that the sugar–phosphodiester backbone slows conformer interchange. Indeed, the ΛHT2 conformer formed and converted to other conformers slowly. Bulkier L (Et4dt versus Me4dt) decreased the abundance of the ΛHT2 conformer, supporting our initial hypothesis that steric crowding disfavors this conformer. The (R4dt)Pt(d(G*pG*)) adducts have a low abundance of the ΔHT1 conformer, consistent with the proposal that the ΔHT1 conformer has an energetically unfavorable phosphodiester backbone conformation; its high abundance when L is bulky is attributed to a small d(G*pG*) spatial footprint for the ΔHT1 conformer. Despite the Goldilocks size of the R4dt ligands, the bases in the (R4dt)Pt(d(G*pG*)) adducts have a low degree of canting, suggesting that the ligand NH groups characteristic of active drugs may facilitate canting, an important aspect of DNA distortions induced by active drugs.Keywords
This publication has 75 references indexed in Scilit:
- Platinum Drug Distribution in Cancer Cells and TumorsChemical Reviews, 2009
- Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDACoordination Chemistry Reviews, 2009
- Inhibition of transcription by platinum antitumor compoundsMetallomics, 2009
- Platinum Anticancer Coordination Compounds: Study of DNA Binding Inspires New Drug DesignEuropean Journal of Inorganic Chemistry, 2009
- cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospectsProceedings of the National Academy of Sciences of the United States of America, 2008
- NMR and X-ray Structural Characterization of a Cisplatin Analogue Able To Slow Down the Pt−N7 Rotation of a Coordinated Guanine Base by a Billion-Fold Times: 2,2′-Bipiperidine(dimethylmalonato)platinum(II) ComplexInorganic Chemistry, 2008
- A 1,2-d(GpG) Cisplatin Intrastrand Cross-Link Influences the Rotational and Translational Setting of DNA in NucleosomesJournal of the American Chemical Society, 2008
- Synthesis, Biophysical Studies, and Antiproliferative Activity of Platinum(II) Complexes Having 1,2-Bis(aminomethyl)carbobicyclic LigandsJournal of Medicinal Chemistry, 2008
- "Platinum on the road": Interactions of antitumoral cisplatin with proteinsPure and Applied Chemistry, 2008
- Antitumour metal compounds: more than theme and variationsDalton Transactions, 2007